ALK and retinal disorder: A phase 1 study, in which ALK-001 was administered to 40healthy adult volunteers, has been completed (NCT02230228), after which the phase II study, where 50ABCA4-associated retinopathy cases were administeredwith either ALK-001 or placebo at a daily basis, was initiated.